source
- Gilead agrees to pay $1.28 billion upfront to China's PepStar for oral IL-23 inflammation drug candidateGilead Sciences announced a deal with Chinese biotech PepStar Therapeutics to acquire an early-stage oral IL-23 inhibitor. The agreement includes an upfront payment of roughly $1.28 billion for Pe…
- Roche signs up to $813M deal with Zymeworks for preclinical trispecific T cell engagerRoche announced a partnership with Zymeworks that includes an upfront payment of $55 million for worldwide rights to a trispecific T cell engager currently in preclinical development. The agreemen…